Search
Glendale, CA Paid Clinical Trials
A listing of 97 clinical trials in Glendale, CA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
61 - 72 of 97
There are currently 97 clinical trials in Glendale, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Glendale Adventist Medical Center, Behavioral Research Specialists, LLC, Glendale Memorial Hospital and Health Center and Global Research Management. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Offer
Join Thousands Waiting for Retatrutide
Retatrutide could change the weight loss landscape. Unlike semaglutide or tirzepatide, it activates three hormone receptors simultaneously — and early data shows it:
✅ Outpaced existing GLP-1 medications for weight loss in clinical trials
✅ Improved blood sugar, blood pressure, and cholesterol beyond weight loss alone
✅ Delivered results with a simple once-weekly injection
✅ Now in Phase 3 trials with FDA submission expected in the next 1–2 years
Join the waiting list. One email when it launches — that's it.
✅ Outpaced existing GLP-1 medications for weight loss in clinical trials
✅ Improved blood sugar, blood pressure, and cholesterol beyond weight loss alone
✅ Delivered results with a simple once-weekly injection
✅ Now in Phase 3 trials with FDA submission expected in the next 1–2 years
Join the waiting list. One email when it launches — that's it.
Conditions:
Weight Loss
Featured Offer
Discover Affordable Semaglutide Providers
We Checked the Checkout Page on Every Semaglutide Provider. Here's What We Found.
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
Conditions:
Weight Loss
Morbid Obesity
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Discover Clinical Trials In Your Area (Compensation Provided)
Recruiting
Clinical trials in your area are actively enrolling — and they compensate you for your time. Finding the right one has never been easier.
- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify
- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify
Conditions:
Healthy
Healthy Volunteers
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part B).
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
07/07/2025
Locations: California Clinical Trials Medical Group (CCTMG), Glendale, California
Conditions: Healthy Participants, Hemophilia A, Hemophilia B
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Recruiting
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.
Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blin... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/07/2025
Locations: Local Institution - 2120, Glendale, California
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Fenofibrate for Prevention of DR Worsening
Recruiting
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline.
In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the dru... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/26/2025
Locations: Kent W. Small, MD, AMC, Glendale, California
Conditions: Diabetic Retinopathy
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Recruiting
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/26/2025
Locations: Kent W. Small, MD, AMC, Glendale, California
Conditions: Neovascular Age-related Macular Degeneration
Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM
Recruiting
Vitrectomy to remove an epiretinal membrane (ERM) is one of the most common procedures performed by retinal surgeons. Patients who present with significant macular changes on optical coherence tomography (OCT) but relatively good vision are often advised to defer surgery until vision declines to 20/40 or worse. However, it is unknown if delaying surgery, which allows the foveal architecture to remain compromised and potentially to deteriorate, results in worse visual acuity outcomes than if surg... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/26/2025
Locations: Kent W. Small, MD, AMC, Glendale, California
Conditions: Epiretinal Membrane
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Recruiting
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
Gender:
ALL
Ages:
Between 12 years and 45 years
Trial Updated:
06/18/2025
Locations: Cortica Healthcare, Glendale, California
Conditions: Autism Spectrum Disorder
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Recruiting
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant.
This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo).
The study will include the following stages:
1. Screening, approximately 35 days
2. 42-day Treatment Period
3. 2-week post do... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Autobahn Site #124, Glendale, California
Conditions: Major Depressive Disorder
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
Recruiting
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are:
1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion
2. Can SNK01 administration improve cognitive assessment scores and biomarkers
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
06/16/2025
Locations: Behavioral Research Specialists, LLC, Glendale, California
Conditions: Moderate Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/06/2025
Locations: Global Research Management, Inc. - Lugene Eye Institute, Glendale, California
Conditions: Wet Age-related Macular Degeneration
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: Glendale Adventist Medical Center, Glendale, California
Conditions: Relapsing Multiple Sclerosis
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:
* Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide)
* Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Los Angeles Cancer Network, Glendale, California
Conditions: Extensive Stage Small Cell Lung Cancer
A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
Recruiting
The primary purpose of this study is to assess the safety and tolerability of oral glovadalen (UCB0022) in healthy Caucasian, Japanese, and Chinese participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/12/2025
Locations: Up0135 1001, Glendale, California
Conditions: Healthy Study Participants
61 - 72 of 97
